Astellas Submits NDA For First Restless Leg Syndrome Drug In Japan
This article was originally published in PharmAsia News
Executive Summary
Astellas submitted an NDA Nov. 19 for restless leg syndrome drug ASP8825 with Japan's Ministry of Health, Labor and Welfare